Genetic Variation in the Cytochrome P450 Epoxygenase Pathway and Cardiovascular Disease Risk

• Rendic S , Di Carlo FJ: Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev.29, 413–580 (1997).
   PubMed Web of Science ®Google Scholar
• Brash AR : Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate.J. Biol. Chem.274, 23679–23682 (1999).
   PubMed Web of Science ®Google Scholar
• Kuehl FA Jr, Egan RW: Prostaglandins, arachidonic acid, and inflammation. Science210, 978–984 (1980).
   PubMed Web of Science ®Google Scholar
• Smith WL , GaravitoRM, DeWittDL: Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2.J. Biol. Chem.271, 33157–33160 (1996).
   PubMed Web of Science ®Google Scholar
• Roman RJ : P-450 metabolites of arachidonic acid in the control of cardiovascular function.Physiol. Rev.82, 131–185 (2002).
   PubMed Web of Science ®Google Scholar
• Zeldin DC : Epoxygenase pathways of arachidonic acid metabolism.J. Biol. Chem.276, 36059–36062 (2001).
   PubMed Web of Science ®Google Scholar
• Enayetallah AE , FrenchRA, ThibodeauMS, GrantDF: Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues.J. Histochem. Cytochem.52, 447–454 (2004).
   PubMed Web of Science ®Google Scholar
• Node K , HuoY, RuanX et al.: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.Science285, 1276–1279 (1999).
   PubMed Web of Science ®Google Scholar
• Larsen BT , MiuraH, HatoumOA et al.: Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition.Am. J. Physiol. Heart Circ. Physiol.290, H491–499 (2006).
   PubMed Web of Science ®Google Scholar
• Campbell WB , GebremedhinD, PrattPF, HarderDR: Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors.Circ. Res.78, 415–423 (1996).
   PubMed Web of Science ®Google Scholar
• Fisslthaler B , PoppR, KissL et al.: Cytochrome P450 2C is an EDHF synthase in coronary arteries.Nature401, 493–497 (1999).
   PubMed Web of Science ®Google Scholar
• Liu Y , ZhangY, SchmelzerK et al.: The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase.Proc. Natl Acad. Sci. USA102, 16747–16752 (2005).
   PubMed Web of Science ®Google Scholar
• Schmelzer KR , KubalaL, NewmanJW, Kim IH, Eiserich JP, Hammock BD: Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl Acad. Sci. USA102, 9772–9777 (2005).
   PubMed Web of Science ®Google Scholar
• Seubert J , YangB, BradburyJA et al.: Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway.Circ. Res.95, 506–514 (2004).
   PubMed Web of Science ®Google Scholar
• Seubert JM , SinalCJ, GravesJ et al.: Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function.Circ. Res.99, 442–450 (2006).
   PubMed Web of Science ®Google Scholar
• Dorrance AM , RuppN, PollockDM, NewmanJW, HammockBD, ImigJD: An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats.J. Cardiovasc. Pharmacol.46, 842–848 (2005).
   PubMed Web of Science ®Google Scholar
• Koerner IP , JacksR, DeBarberAE et al.: Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury.J. Neurosci.27, 4642–4649 (2007).
   PubMed Web of Science ®Google Scholar
• Node K , RuanXL, DaiJ et al.: Activation of G alphas mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids.J. Biol. Chem.276, 15983–15989 (2001).
   PubMed Web of Science ®Google Scholar
• Munzenmaier DH , HarderDR: Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release.Am. J. Physiol. Heart Circ. Physiol.278, H1163–1167 (2000).
   PubMed Web of Science ®Google Scholar
• Sun J , SuiX, BradburyJA, ZeldinDC, ConteMS, LiaoJK: Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids.Circ. Res.90, 1020–1027 (2002).
   PubMed Web of Science ®Google Scholar
• Sinal CJ , MiyataM, TohkinM, NagataK, BendJR, GonzalezFJ: Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation.J. Biol. Chem.275, 40504–40510 (2000).
   PubMed Web of Science ®Google Scholar
• Imig JD , ZhaoX, CapdevilaJH, Morisseau C, Hammock BD: Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension39, 690–694 (2002).
   PubMed Web of Science ®Google Scholar
• Imig JD , ZhaoX, ZaharisCZ et al.: An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.Hypertension46, 975–981 (2005).
   PubMed Web of Science ®Google Scholar
• de Winther MP , KantersE, KraalG, Hofker MH: Nuclear factor κB signaling in atherogenesis. Arterioscler. Thromb. Vasc. Biol.25, 904–914 (2005).
   PubMed Web of Science ®Google Scholar
• Cowart LA , WeiS, HsuMH et al.: The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands.J. Biol. Chem.277, 35105–35112 (2002).
   PubMed Web of Science ®Google Scholar
• Wu S , MoomawCR, TomerKB, FalckJR, ZeldinDC: Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart.J. Biol. Chem.271, 3460–3468 (1996).
   PubMed Web of Science ®Google Scholar
• Gaedigk A , BakerDW, TotahRA et al.: Variability of CYP2J2 expression in human fetal tissues.J. Pharmacol. Exp. Ther.319, 523–532 (2006).
   PubMed Web of Science ®Google Scholar
• King LM , MaJ, SrettabunjongS et al.: Cloning of CYP2J2 gene and identification of functional polymorphisms.Mol. Pharmacol.61, 840–852 (2002).
   PubMed Web of Science ®Google Scholar
• Lee SS , JeongHE, LiuKH et al.: Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity.Pharmacogenet. Genomics15, 105–113 (2005).
   PubMed Web of Science ®Google Scholar
• Yamazaki H , OkayamaA, ImaiN, GuengerichFP, ShimizuM: Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations.Xenobiotica36, 1201–1209 (2006).
   PubMed Web of Science ®Google Scholar
• Spiecker M , DariusH, HankelnT et al.: Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2.Circulation110, 2132–2136 (2004).
   PubMed Web of Science ®Google Scholar
• Liu PY , LiYH, ChaoTH et al.: Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction.Atherosclerosis (2006) (Epub ahead of print).
   Web of Science ®Google Scholar
• Spiecker M , ZeldinDC, MuggeA, TenderichG, LiaoJK, MiltingH: Reduced human myocardial mRNA expression of CYP2J2 in individuals with the G-50T promoter polymorphism. American Heart Association Scientific Sessions. Chicago, USA,Circulation691, II-117 (2006).
   Google Scholar
• Hoffmann MM , BugertP, SeelhorstU et al.: The -50G>T polymorphism in the promoter of the CYP2J2 gene in coronary heart disease: the Ludwigshafen Risk and Cardiovascular Health study.Clin. Chem.53, 539–540 (2007).
   PubMed Web of Science ®Google Scholar
• Lee CR , NorthKE, BrayMS, CouperDJ, HeissG, ZeldinDC: CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study.Pharmacogenet. Genomics17, 349–358 (2007).
   PubMed Web of Science ®Google Scholar
• King LM , GainerJV, DavidGL et al.: Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension.Pharmacogenet. Genomics15, 7–13 (2005).
   PubMedGoogle Scholar
• Wu SN , ZhangY, GardnerCO et al.: Evidence for association of polymorphisms in CYP2J2 and susceptibility to essential hypertension. Ann. Hum. Genet. 71, 519–525 (2007).
   Google Scholar
• Dreisbach AW , JapaS, SigelA et al.: The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension.Am. J. Hypertens.18, 1276–1281 (2005).
   PubMed Web of Science ®Google Scholar
• Pucci L , LucchesiD, ChirulliV et al.: Cytochrome P450 2J2 polymorphism in healthy Caucasians and those with diabetes mellitus.Am. J. Pharmacogenomics.3, 355–358 (2003).
   PubMedGoogle Scholar
• Goldstein JA , de Morais SM: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics4, 285–299 (1994).
   PubMedGoogle Scholar
• Klose TS , BlaisdellJA, GoldsteinJA: Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs.J. Biochem. Mol. Toxicol.13, 289–295 (1999).
   PubMed Web of Science ®Google Scholar
• Yasar U , LundgrenS, EliassonE et al.: Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.Biochem. Biophys. Res. Commun.299, 25–28 (2002).
   PubMed Web of Science ®Google Scholar
• Totah RA , RettieAE: Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance.Clin. Pharmacol. Ther.77, 341–352 (2005).
   PubMed Web of Science ®Google Scholar
• Lee CR , GoldsteinJA, PieperJA: Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data.Pharmacogenetics12, 251–263 (2002).
   PubMedGoogle Scholar
• Bahadur N , LeathartJB, MutchE et al.: CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes.Biochem. Pharmacol.64, 1579–1589 (2002).
   PubMed Web of Science ®Google Scholar
• Dai D , ZeldinDC, BlaisdellJA et al.: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.Pharmacogenetics11, 597–607 (2001).
   PubMedGoogle Scholar
• Soyama A , SaitoY, HaniokaN et al.: Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism.Biol. Pharm. Bull.24, 1427–1430 (2001).
   PubMed Web of Science ®Google Scholar
• Lundblad MS , StarkK, EliassonE, OliwE, RaneA: Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes.Biochem. Biophys. Res. Commun.327, 1052–1057 (2005).
   PubMed Web of Science ®Google Scholar
• Rettie AE , WienkersLC, GonzalezFJ, TragerWF, KorzekwaKR: Impaired S-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.Pharmacogenetics4, 39–42 (1994).
   PubMedGoogle Scholar
• Sullivan-Klose TH , GhanayemBI, BellDA et al.: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics6, 341–349 (1996).
   PubMedGoogle Scholar
• Yasar U , BennetAM, EliassonE et al.: Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction.Pharmacogenetics13, 715–720 (2003).
   PubMedGoogle Scholar
• Visser LE , van Schaik RH, Jan Danser AH et al.: The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Pharmacogenet. Genomics17, 473–479 (2007).
   PubMed Web of Science ®Google Scholar
• Newman JW , MorisseauC, HarrisTR, HammockBD: The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity.Proc. Natl Acad. Sci. USA100, 1558–1563 (2003).
   PubMed Web of Science ®Google Scholar
• Sandberg M , MeijerJ: Structural characterization of the human soluble epoxide hydrolase gene (EPHX2).Biochem. Biophys. Res. Commun.221, 333–339 (1996).
   PubMed Web of Science ®Google Scholar
• Srivastava PK , SharmaVK, KaloniaDS, GrantDF: Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure.Arch. Biochem. Biophys.427, 164–169 (2004).
   PubMed Web of Science ®Google Scholar
• Przybyla-Zawislak BD , SrivastavaPK, Vazquez-MatiasJ et al.: Polymorphisms in human soluble epoxide hydrolase.Mol. Pharmacol.64, 482–490 (2003).
   PubMed Web of Science ®Google Scholar
• Sandberg M , HassettC, AdmanET, Meijer J, Omiecinski CJ: Identification and functional characterization of human soluble epoxide hydrolase genetic polymorphisms. J. Biol. Chem.275, 28873–28881 (2000).
   PubMed Web of Science ®Google Scholar
• Lee CR , NorthKE, BrayMS et al.: Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study.Hum. Mol. Genet.15, 1640–1649 (2006).
   PubMed Web of Science ®Google Scholar
• Fornage M , BoerwinkleE, DorisPA, Jacobs D, Liu K, Wong ND: Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African–American subjects: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation109, 335–339 (2004).
   PubMed Web of Science ®Google Scholar
• Wei Q , DorisPA, PollizottoMV et al.: Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking.Atherosclerosis190, 26–34 (2007).
   PubMed Web of Science ®Google Scholar
• Fornage M , LeeCR, DorisPA et al.: The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke.Hum. Mol. Genet.14, 2829–2837 (2005).
   PubMed Web of Science ®Google Scholar
• Sato K , EmiM, EzuraY et al.: Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred.J. Hum. Genet.49, 29–34 (2004).
   PubMed Web of Science ®Google Scholar
• Ohtoshi K , KanetoH, NodeK et al.: Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in Type 2 diabetic patients.Biochem. Biophys. Res. Commun.331, 347–350 (2005).
   PubMed Web of Science ®Google Scholar
• Chanock SJ , ManolioT, BoehnkeM et al.: Replicating genotype–phenotype associations.Nature447, 655–660 (2007).
   PubMed Web of Science ®Google Scholar
• Colhoun HM , McKeiguePM, Davey Smith G: Problems of reporting genetic associations with complex outcomes. Lancet361, 865–872 (2003).
   PubMed Web of Science ®Google Scholar
• Zondervan KT , CardonLR: The complex interplay among factors that influence allelic association.Nat. Rev. Genet.5, 89–100 (2004).
   PubMed Web of Science ®Google Scholar
• Sayed-Tabatabaei FA , OostraBA, IsaacsA, van Duijn CM, Witteman JC: ACE polymorphisms. Circ. Res.98, 1123–1133 (2006).
   PubMed Web of Science ®Google Scholar
• Casas JP , CavalleriGL, BautistaLE, Smeeth L, Humphries SE, Hingorani AD: Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am. J. Epidemiol.164, 921–935 (2006).
   PubMed Web of Science ®Google Scholar
• Brodde OE , BruckH, LeineweberK: Cardiac adrenoceptors: physiological and pathophysiological relevance.J. Pharmacol. Sci.100, 323–337 (2006).
   PubMed Web of Science ®Google Scholar
• Kawashima S , YokoyamaM: Dysfunction of endothelial nitric oxide synthase and atherosclerosis.Arterioscler. Thromb. Vasc. Biol.24, 998–1005 (2004).
   PubMed Web of Science ®Google Scholar
• Ambrose JA , BaruaRS: The pathophysiology of cigarette smoking and cardiovascular disease: an update.J. Am. Coll. Cardiol.43, 1731–1737 (2004).
   PubMed Web of Science ®Google Scholar
• Imig JD : Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors.Cardiovasc. Drug Rev.24, 169–188 (2006).
   PubMed Web of Science ®Google Scholar
• The ARIC Investigators: The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am. J. Epidemiol.129, 687–702 (1989).
   PubMed Web of Science ®Google Scholar

Websites

• Homepage of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee www.cypalleles.ki.se/
   Google Scholar